Byrne Asset Management LLC Relmada Therapeutics, Inc. Transaction History

Byrne Asset Management LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 30, 2023	SELL	$2.17 - $35.84 $7,592 - $125,404	-3,499 Reduced 99.97%	1 $0
Q2 2022 Jul 20, 2022	SELL	$16.5 - $30.34 $52,387 - $96,329	-3,175 Reduced 47.57%	3,500 $66,000
Q1 2022 Apr 05, 2022	BUY	$16.72 - $26.99 $14,629 - $23,616	875 Added 15.09%	6,675 $180,000
Q4 2021 Feb 22, 2022	BUY	$16.93 - $26.82 $98,194 - $155,556	5,800 New	5,800 $131,000

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Byrne Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Byrne Asset Management LLC with notifications on news.